CH480294A - Process for the production of basic thymyl ethers - Google Patents
Process for the production of basic thymyl ethersInfo
- Publication number
- CH480294A CH480294A CH340467A CH340467A CH480294A CH 480294 A CH480294 A CH 480294A CH 340467 A CH340467 A CH 340467A CH 340467 A CH340467 A CH 340467A CH 480294 A CH480294 A CH 480294A
- Authority
- CH
- Switzerland
- Prior art keywords
- sep
- compound
- ether
- compounds
- chlorothymyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- -1 thymyl ethers Chemical class 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 claims description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 4
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 238000004508 fractional distillation Methods 0.000 claims 2
- VWVZFHRDLPHBEG-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfanylbenzene Chemical group CSC1=CC=C(CCl)C=C1 VWVZFHRDLPHBEG-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 3
- 230000000948 sympatholitic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000000219 Sympatholytic Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Verfahren zur Herstellung von basischen Thymyläthern Es wurde bereits ein Verfahren zur Herstellung von basischen Thymyläthern der allgemeinen Formel
EMI0001.0000
vorgeschlagen. Die Verbindungen sind durch sympathikolytisch- adrenolytische Eigenschaften ausgezeichnet. Dosen von 0,5 mg/kg rufen am Katzen-Blutdruck eine Adrenalin- Umkehr bzw. eine Abschwächung oder Aufhebung der pressorischen Noradrenalin-Wirkung hervor. Die Wir kungsdauer beträgt 8 Stunden und mehr.
Es hat sich nun gezeigt, dass die Einführung einer seitenständigen Methylgruppe an der Äthylenbrücke zwischen dem Sauerstoff- und dem Stickstoffatom die Toxizität in überraschendem Umfange, bei völliger Er haltung oder Verstärkung der sympathikolytischen Wirksamkeit, verringert. Die entsprechenden Verbindun gen sind pharmazeutische Produkte, die eine in dieser chemischen Körperklasse bisher nicht erreichte, grosse therapeutische Breite besitzen.
Zum Beispiel ergaben sich für die 4-Chlorthymyl- äther
EMI0001.0006
EMI0001.0007
folgende <SEP> Werte:
<tb> Verbindung <SEP> R <SEP> R' <SEP> Toxizität <SEP> Kleinste <SEP> Dosis <SEP> Therapeu- <SEP> Relative
<tb> sc.
<SEP> mg/kg <SEP> für <SEP> Adrenalin- <SEP> tische <SEP> therapeutische
<tb> Maus <SEP> Umkehr <SEP> am <SEP> Breite <SEP> Breite
<tb> Katzenblutdruck
<tb> WV <SEP> 781 <SEP> H <SEP> H <SEP> 105 <SEP> 1,0 <SEP> mg/kg <SEP> 105 <SEP> 1
<tb> WV <SEP> 0052 <SEP> CH3 <SEP> 11 <SEP> 210 <SEP> 0,5 <SEP> mg/kg <SEP> 420 <SEP> 4
<tb> WV <SEP> 0062 <SEP> H <SEP> CH3 <SEP> 130 <SEP> 0,35 <SEP> mg/kg <SEP> 370 <SEP> 3,5 Wie aus der Tabelle ersichtlich, verringert die Ein führung einer seitenständigen Methylgruppe in Nach barschaft zum Sauerstoff die Toxizität auf die Hälfte und verdoppelt die sympathikolytische Wirksamkeit.
So mit steigert sich die therapeutische Breite auf das 4- fache. Überraschend ist auch die Wirkung einer seiten- ständigen Methylgruppe in Nachbarschaft zum Stick stoff: die Toxizität wird verringert, die sympathikolyti- sche Wirksamkeit gesteigert.
Diese Befunde bedeuten einen weiteren Fortschritt für die Therapie des Hypertonus und der peripheren Durchblutungsstörungen.
Zur Herstellung der neuen Verbindungen wird ein entsprechender 4-Chlor- bzw. 4-Brom-thymyl-hydroxy- propyläther, den man sich aus dem entsprechenden Ha logenthymol und Propylenoxyd beziehungsweise Halo genthymol-Natrium und Halogenpropanol bereiten kann, hydrochloriert und weiter mit Äthylamino- äthanol und Thionylchlorid bzw. -bromid umgesetzt.
Das geschilderte Verfahren liefert, wenn mit Thio- nylchlorid gearbeitet wird, die ss-Chloräthylverbindun- gen. Zur Herstellung der ss-Bromäthylverbindungen kann man entweder Thionylbromid an Stelle von Thio- nylchlorid verwenden oder aber die ss-Chloräthylver- bindungen mit Natriumbromid in Alkohol oder mit Lithiumbromid in Aceton umsetzen.
Die Hydrochloride der neuen Verbindungen können in üblicher Weise in Salze anderer Säuren umgewan delt werden, zum Beispiel in Hydrobromide, 1,5-Naph- thalindisulfonate, Maleinate und andere mehr. Man setzt z. B. entweder mit Alkali die organische Base in Frei heit, nimmt in einem geeigneten organischen Lösemittel auf und neutralisiert mit der gewünschten Säure oder setzt z. B. bei geeigneten Löslichkeitsverhältnissen das Hydrochlorid mit dem Alkali- oder Silbersalz der ge wünschten Säure um.
EMI0002.0020
Nach dem gleichen Verfahren erhält man mit 2- Chlorpropanol-1 als Ausgangsmaterial die isomere Ver bindung WV 0052.
e) 4-Chlorthymyl-[N-äthyl-N-ss-chloräthyl- aminoisopropyl-(1)]-äther-naphthalin-1,5-disulfonat Eine wässrige Lösung der Substanz d) wird mit ge sättigter wässriger Naphthalin 1,5-disulfonsäure ver setzt. Das Naphthalindisulfonat fällt in fast quantitati ver Ausbeute aus.
Fp. 198-200 C.
Process for the preparation of basic thymyl ethers There has already been a process for the preparation of basic thymyl ethers of the general formula
EMI0001.0000
suggested. The compounds are distinguished by sympatholytic-adrenolytic properties. Doses of 0.5 mg / kg induce an adrenaline reversal or a weakening or abolition of the pressoric noradrenaline effect in the cat's blood pressure. The duration of action is 8 hours and more.
It has now been shown that the introduction of a pendant methyl group on the ethylene bridge between the oxygen and nitrogen atom reduces the toxicity to a surprising extent, with complete retention or enhancement of the sympatholytic activity. The corresponding compounds are pharmaceutical products that have a wide therapeutic range not previously achieved in this chemical body class.
For example, the 4-chlorothymyl ethers resulted
EMI0001.0006
EMI0001.0007
the following <SEP> values:
<tb> Compound <SEP> R <SEP> R '<SEP> Toxicity <SEP> Smallest <SEP> dose <SEP> Therapeu- <SEP> Relative
<tb> sc.
<SEP> mg / kg <SEP> for <SEP> adrenaline <SEP> table <SEP> therapeutic
<tb> mouse <SEP> reverse <SEP> on <SEP> width <SEP> width
<tb> cat blood pressure
<tb> WV <SEP> 781 <SEP> H <SEP> H <SEP> 105 <SEP> 1.0 <SEP> mg / kg <SEP> 105 <SEP> 1
<tb> WV <SEP> 0052 <SEP> CH3 <SEP> 11 <SEP> 210 <SEP> 0.5 <SEP> mg / kg <SEP> 420 <SEP> 4
<tb> WV <SEP> 0062 <SEP> H <SEP> CH3 <SEP> 130 <SEP> 0.35 <SEP> mg / kg <SEP> 370 <SEP> 3.5 As can be seen from the table, the The introduction of a side methyl group in the vicinity of oxygen halves the toxicity and doubles the sympatholytic effectiveness.
This increases the therapeutic range by a factor of four. The effect of a methyl group in the vicinity of the nitrogen is also surprising: toxicity is reduced and sympatholytic efficacy is increased.
These findings represent a further step forward in the therapy of hypertension and peripheral circulatory disorders.
To produce the new compounds, a corresponding 4-chloro- or 4-bromo-thymyl-hydroxypropyl ether, which can be prepared from the corresponding halogen thymol and propylene oxide or halo genthymol sodium and halopropanol, is hydrochlorinated and further with ethylamino- Ethanol and thionyl chloride or bromide implemented.
If thionyl chloride is used, the process described gives the ß-chloroethyl compounds. To prepare the ß-bromoethyl compounds, either thionyl bromide can be used instead of thionyl chloride or the ß-chloroethyl compounds with sodium bromide in alcohol or react with lithium bromide in acetone.
The hydrochlorides of the new compounds can be converted in the usual manner into salts of other acids, for example into hydrobromides, 1,5-naphthalene disulfonates, maleinates and others. One sets z. B. either with alkali the organic base in free unit, takes up in a suitable organic solvent and neutralized with the desired acid or sets z. B. with suitable solubility conditions, the hydrochloride with the alkali or silver salt of the ge desired acid.
EMI0002.0020
The isomeric compound WV 0052 is obtained by the same procedure with 2-chloropropanol-1 as the starting material.
e) 4-chlorothymyl- [N-ethyl-N-ss-chloroethyl- aminoisopropyl- (1)] - ether-naphthalene-1,5-disulfonate An aqueous solution of substance d) is mixed with saturated aqueous naphthalene 1,5- disulfonic acid ver. The naphthalene disulfonate precipitates in almost quantitative yield.
M.p. 198-200 C.
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DED40371A DE1200322B (en) | 1962-11-28 | 1962-11-28 | Process for the production of basic thymyl ethers |
| CH1415163A CH464225A (en) | 1962-11-28 | 1963-11-19 | Process for the production of basic thymyl ethers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH480294A true CH480294A (en) | 1969-10-31 |
Family
ID=25713707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH340467A CH480294A (en) | 1962-11-28 | 1963-11-19 | Process for the production of basic thymyl ethers |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH480294A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0269363A3 (en) * | 1986-11-21 | 1989-11-23 | A/S Cheminova | Amino-alkylated hydroxy compounds and their use as fungicides |
-
1963
- 1963-11-19 CH CH340467A patent/CH480294A/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0269363A3 (en) * | 1986-11-21 | 1989-11-23 | A/S Cheminova | Amino-alkylated hydroxy compounds and their use as fungicides |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2502916C2 (en) | ||
| DE1720018A1 (en) | N-monosubstituted pyrrylaminoethanols and process for their preparation | |
| DE2016839C3 (en) | PhenyM4-phenoxyphenyi) -imidazol-1-yl-methane, process for their preparation and pharmaceuticals containing these compounds | |
| DE2130673A1 (en) | Diphenylmethylimidazoles, process for their preparation and their use as fungicides | |
| AT344151B (en) | PROCESS FOR PRODUCING NEW NAPHTHALIN DERIVATIVES | |
| CH480294A (en) | Process for the production of basic thymyl ethers | |
| DE1915230B2 (en) | HYDROXYPHENYLALKYLAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS ON THE BASIS OF THEM | |
| DE1933112B2 (en) | Substituted 1,3-bis (benzylideneamino) guanidine | |
| DE2817370A1 (en) | PHENYLTETRAZOLYLOXY PROPANOLAMINE, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PRODUCTS CONTAINING THESE | |
| DE3016549C2 (en) | 2-Isopropylamino-5-halogenopyrimidines, processes for their preparation and therapeutic compositions containing them | |
| DE1695785C3 (en) | 2-aminomethyl-beitzofurans, processes for their production and preparations containing these compounds | |
| CH464225A (en) | Process for the production of basic thymyl ethers | |
| DE2609574C3 (en) | 1 - ^ - Fluoro-S-trifluoromethylthiophenyD-piperazine, its salts, process for its preparation and pharmaceuticals | |
| DE1795133C2 (en) | 5-nitro-8- (5'-bromo-alpha-furoyloxy) -quinaldine, a process for its preparation and pharmaceuticals | |
| DE2437272A1 (en) | BENZOTHIADIAZINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PREPARATIONS CONTAINING THEM | |
| DE946058C (en) | Process for the preparation of 3-aminoindanes | |
| DE2217202C3 (en) | 5-substituted benzophenone hydrazone compounds, processes for their preparation and pharmaceutical preparations containing these compounds | |
| DE1543673C3 (en) | Basically substituted benzofuran derivatives and their pharmaceutically acceptable acid addition salts, as well as processes for their production and pharmaceuticals containing these compounds | |
| AT233575B (en) | Process for the preparation of new piperazine salts | |
| AT257058B (en) | Process for the preparation of the new bis-pyridylmethyl disulfide | |
| DE1643459C3 (en) | 1 - (2-Methoxyphenoxy) -3-tert-butylamino-2-propanol and its salts, processes for their preparation and pharmaceuticals | |
| DE2822326A1 (en) | ANTIMYCOTIC AGENTS | |
| DE2329895C3 (en) | N- (4-picolyl) -3,5-dimethylbenzamide | |
| DE1543369C3 (en) | l-aryloxy-2-aminoalkanes and pharmaceutical preparations based thereon | |
| AT267511B (en) | Process for the preparation of new 1-phenyl-1- (2'-aminoethyl) -indenes and their salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |